Using a Mobile Health Intervention (DOT Selfie) With Transfer of Social Bundle Incentives to Increase Treatment Adherence in Tuberculosis Patients in Uganda: Protocol for a Randomized Controlled Trial

• Published in: JMIR research protocols Vol. 10; no. 1; p. e18029
• Main Authors: Sekandi, Juliet Nabbuye, Onuoha, Nicole Amara, Buregyeya, Esther, Zalwango, Sarah, Kaggwa, Patrick Evans, Nakkonde, Damalie, Kakaire, Robert, Atuyambe, Lynn, Whalen, Christopher C, Dobbin, Kevin K
• Format: Journal Article
• Language: English
• Published: Canada JMIR Publications 05.01.2021
• Subjects: Clinics; Drug resistance; Enrollments; Intervention; Medical research; Patient compliance; Patients; Protocol; Questionnaires; Research methodology; Smartphones; Text messaging; Tuberculosis; Uganda; California; United States > US; Kampala Uganda; Africa; DOT Selfie; digital health; directly observed therapy; treatment adherence; Africa; tuberculosis; mHealth; video observed therapy; eHealth
• ISSN: 1929-0748; 1929-0748
• DOI: 10.2196/18029

The World Health Organization's End TB Strategy envisions a world free of tuberculosis (TB)-free of deaths, disease, and suffering due to TB-by 2035. Nonadherence reduces cure rates, prolongs infectiousness, and contributes to the emergence of multidrug-resistant TB (MDR-TB). Moreover, MDR-TB is a growing, complex, and costly problem that presents a major obstacle to TB control. Directly observed therapy (DOT) for treatment adherence monitoring is the recommended standard; however, it is challenging to implement at scale because it is labor-intensive. Mobile health interventions can facilitate remote adherence monitoring and minimize the costs and inconveniences associated with standard DOT. The study aims to evaluate the effectiveness of using video directly observed therapy (VDOT) plus incentives to improve medication adherence in TB treatment versus usual-care DOT in an African context. The DOT Selfie study is an open-label, randomized controlled trial (RCT) with 2 parallel groups, in which 144 adult patients with TB aged 18-65 years will be randomly assigned to receive the usual-care DOT monitoring or VDOT as the intervention. The intervention will consist of a smartphone app, a weekly internet subscription, translated text message reminders, and incentives for those who adhere. The participant will use a smartphone to record and send time-stamped encrypted videos showing their daily medication ingestion. This video component will directly substitute the need for daily face-to-face meetings between the health provider and patients. We hypothesize that the VDOT intervention will be more effective because it allows patients to swallow their pills anywhere, anytime. Moreover, patients will receive mobile-phone-based "social bundle" incentives to motivate adherence to continued daily submission of videos to the health system. The health providers will log into a secured computer system to verify treatment adherence, document missed doses, investigate the reasons for missed doses, and follow prespecified protocol measures to re-establish medication adherence. The primary endpoint is the adherence level as measured by the fraction of expected doses observed over the treatment period. The main secondary outcome will be time-to-treatment completion in both groups. This study was funded in 2019. Enrollment began in July and is expected to be completed by November 2020. Data collection and follow-up are expected to be completed by June 2021. Results from the analyses based on the primary endpoint are expected to be submitted for publication by December 2021. This random control trial will be among the first to evaluate the effectiveness of VDOT within an African setting. The results will provide robust scientific evidence on the implementation and adoption of mobile health (mHealth) tools, coupled with incentives to motivate TB medication adherence. If successful, VDOT will apply to other low-income settings and a range of chronic diseases with lifelong treatment, such as HIV/AIDs. ClinicalTrials.gov NCT04134689; http://clinicaltrials.gov/ct2/show/NCT04134689. DERR1-10.2196/18029.